OBJECTIVE: To present the results of the clinical study of carbon ion radiotherapy (CIRT) for skull base and paracervical spine tumors at the National Institute of Radiological Sciences in Chiba, Japan. METHODS: The study is comprised of three protocols: a pilot study, a phase I/II dose escalation study, and a phase II study. All the patients were treated by 16 fractions for 4 weeks with total doses of 48.0, 52.8, 57.6, and 60.8 Gy equivalents (GyE). RESULTS: As a result of the dose escalation study of CIRT for skull base tumors, a dose fractionation of 60.8 GyE/16 fractions for 4 weeks was decided as the recommended dose because of acceptable normal tissue reactions and good local tumor control. CONCLUSIONS: Preliminary results of the phase II clinical study of CIRT for skull base chordoma showed local control at 5 years at 100%, and normal tissues showed a mild reaction without any severe morbidity of important organs.
OBJECTIVE: To present the results of the clinical study of carbon ion radiotherapy (CIRT) for skull base and paracervical spine tumors at the National Institute of Radiological Sciences in Chiba, Japan. METHODS: The study is comprised of three protocols: a pilot study, a phase I/II dose escalation study, and a phase II study. All the patients were treated by 16 fractions for 4 weeks with total doses of 48.0, 52.8, 57.6, and 60.8 Gy equivalents (GyE). RESULTS: As a result of the dose escalation study of CIRT for skull base tumors, a dose fractionation of 60.8 GyE/16 fractions for 4 weeks was decided as the recommended dose because of acceptable normal tissue reactions and good local tumor control. CONCLUSIONS: Preliminary results of the phase II clinical study of CIRT for skull base chordoma showed local control at 5 years at 100%, and normal tissues showed a mild reaction without any severe morbidity of important organs.
Entities:
Keywords:
Chordoma; carbon ion radiotherapy; particle radiotherapy; skull base tumor
Authors: T Kanai; M Endo; S Minohara; N Miyahara; H Koyama-ito; H Tomura; N Matsufuji; Y Futami; A Fukumura; T Hiraoka; Y Furusawa; K Ando; M Suzuki; F Soga; K Kawachi Journal: Int J Radiat Oncol Biol Phys Date: 1999-04-01 Impact factor: 7.038
Authors: Damien C Weber; Hans Peter Rutz; Eros S Pedroni; Alessandra Bolsi; Beate Timmermann; Jorn Verwey; Antony J Lomax; Gudrun Goitein Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: A Terahara; A Niemierko; M Goitein; D Finkelstein; E Hug; N Liebsch; D O'Farrell; S Lyons; J Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: J Debus; E B Hug; N J Liebsch; D O'Farrel; D Finkelstein; J Efird; J E Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1997-12-01 Impact factor: 7.038
Authors: Daniela Schulz-Ertner; Christian P Karger; Alexandra Feuerhake; Anna Nikoghosyan; Stephanie E Combs; Oliver Jäkel; Lutz Edler; Michael Scholz; Jürgen Debus Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-23 Impact factor: 7.038
Authors: A Tomiyama; K Tachibana; K Suzuki; S Seino; J Sunayama; K-i Matsuda; A Sato; Y Matsumoto; T Nomiya; K Nemoto; H Yamashita; T Kayama; K Ando; C Kitanaka Journal: Cell Death Dis Date: 2010-07-29 Impact factor: 8.469
Authors: Piero Fossati; Ana Perpar; Markus Stock; Petra Georg; Antonio Carlino; Joanna Gora; Giovanna Martino; Eugen B Hug Journal: Int J Part Ther Date: 2021-06-25